# Effects of Whole-Body Cryostimulation on Stress Biomarkers and Psychological Well-Being in Parkinson’s Disease: A Pilot Study

**Authors:** Paolo Piterà, Stefania Cattaldo, Riccardo Cremascoli, Laura Bianchi, Elisa Prina, Federica Verme, Erica Sabattini, Lorenzo Priano, Alessandro Mauro, Paolo Capodaglio

PMC · DOI: 10.3390/jcm15041602 · 2026-02-19

## TL;DR

A pilot study found that whole-body cryostimulation may reduce stress and improve psychological well-being in Parkinson’s disease patients.

## Contribution

This is the first study to investigate the effects of whole-body cryostimulation on stress biomarkers and psychological symptoms in Parkinson’s disease.

## Key findings

- WBC significantly reduced cortisol levels and improved serotonin levels in Parkinson’s patients.
- Patients showed reduced anxiety, depression, fatigue, and sleepiness after WBC sessions.
- WBC was safe and well-tolerated with no reported adverse effects.

## Abstract

Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized not only by motor impairments but also by debilitating non-motor symptoms (NMS) such as anxiety, depression, fatigue, and sleep disturbances. These symptoms are often resistant to dopaminergic therapies and significantly impact patients’ quality of life. Whole-body cryostimulation (WBC) has emerged as a promising non-pharmacological intervention with potential effects on stress modulation and psychological well-being. Materials and Methods: In total, 14 patients with idiopathic PD underwent 10 WBC sessions (−110 °C for 2 min) over two weeks. Blood samples for cortisol and serotonin were collected before and after the first and last sessions. Patients completed standardized questionnaires evaluating anxiety (STAI-Y1, Y2), depression (BDI), fatigue (FSS), sleep quality (SCI), and daytime sleepiness (ESS) at baseline and after the final session. Results: Significant reductions in serum cortisol and improvements in serotonin levels were observed. Psychological assessments showed decreased anxiety and depression scores, with improvements in fatigue and sleepiness (p < 0.05 for most scales). Discussion and Conclusions: Repeated WBC sessions were safe and well-tolerated and were associated with biochemical and psychological improvements. These preliminary findings support WBC as a promising complementary intervention for alleviating NMS in PD. Further randomized controlled studies are warranted to confirm these results.

## Linked entities

- **Chemicals:** cortisol (PubChem CID 5754), serotonin (PubChem CID 5202)
- **Diseases:** Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Diseases:** cancer (MESH:D009369), orthostatic hypotension (MESH:D007024), neuropsychiatric disturbances (MESH:D001523), tinnitus-related disorders (MESH:D014012), cardiovascular autonomic dysregulation (MESH:D002318), fibromyalgia (MESH:D005356), cryoglobulinemia (MESH:D003449), insomnia (MESH:D007319), asthma (MESH:D001249), Lewy body (MESH:D020961), Anxiety (MESH:D001007), neuroinflammation (MESH:D000090862), weight loss (MESH:D015431), cerebral palsy (MESH:D002547), symptoms (MESH:D012816), spine (MESH:D016135), spasticity (MESH:D009128), neurodegeneration (MESH:D019636), daytime dysfunction (MESH:D006970), injury to (MESH:D014947), inflammatory (MESH:D007249), Parkinsonian syndromes (MESH:D020734), metabolic or neurological disease (MESH:D001928), PD (MESH:D010300), tremor (MESH:D014202), bradykinesia (MESH:D018476), skin injuries (MESH:D000069836), pain (MESH:D010146), Sleep disorders (MESH:D012893), PSP (MESH:D013494), rigidity (MESH:D009127), frostbite (MESH:D005627), hypoglycemic (MESH:C000721848), oncologic (MESH:D000072716), motor deficits (MESH:D009461), sleepiness (MESH:D000077260), metabolic (MESH:D008659), osteoarthrosis (MESH:D010003), non (MESH:C580335), phantom limb syndrome (MESH:D010591), NMS (MESH:D020879), autonomic (MESH:D001342), motor impairments (MESH:D000068079), cognitive dysfunction (MESH:D003072), gait impairments (MESH:D020234), chronic-pain (MESH:D059350), Depression (MESH:D003866), HPA axis hyperactivity (MESH:D007029), BD (MESH:D001528), mood and sleep disorders (MESH:D019964), dementia (MESH:D003704), overweight (MESH:D050177), Serotoninergic dysfunction (MESH:D006331), Fatigue (MESH:D005221), PLP (MESH:C566449), MSA (MESH:D019578)
- **Chemicals:** Cortisol (MESH:D006854), nitrogen (MESH:D009584), carbohydrates (MESH:D002241), simple sugars (MESH:D009005), melatonin (MESH:D008550), levodopa (MESH:D007980), WBC (-), noradrenaline (MESH:D009638), dopamine (MESH:D004298), Serotonin (MESH:D012701)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942333/full.md

---
Source: https://tomesphere.com/paper/PMC12942333